Johnson & Johnson Corp.'s (J&J) plan to reach $302 million in sales of anti-psychotic drug Risperdal by marketing it to the elderly came to the attention of Louisiana officials. The plan came to light just months after federal regulators said the company falsely claimed the drug was safe and effective for dementia treatment.
In State of Louisiana v. Janssen Pharmaceuticals, Louisiana officials cited more than a dozen J&J files and internal documents stating the company's plan to market Risperdal for unapproved uses. Until 2003, the FDA approved Risperdal only for use on psychotic disorders such as schizophrenia. The agency never approved it for dementia.